Literature DB >> 10744061

Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: evidence for a medulloblastoma subtype derived from the external granule cell layer.

J Bühren1, A H Christoph, R Buslei, S Albrecht, O D Wiestler, T Pietsch.   

Abstract

Medulloblastomas (MBs) are primitive neuroectodermal tumors (PNET) of the cerebellum. They represent the most frequent malignant pediatric brain tumors, but their origin still remains unresolved and controversial. MB cells correspond to different stages of neural development and differentiation as illustrated by their expression of neuronal and glial markers. In the present study, we examined the expression pattern of the common low-affinity neurotrophin receptor p75NTR in a series of 167 MBs by immunohistochemistry. While p75NTR was present in only 17% of classic MBs (CMB), we found expression of p75NTR in all desmoplastic (nodular) MBs (DMB) examined, and in 71% of those MBs with a significant desmoplastic component. Furthermore, both desmoplastic histology and p75NTR expression were present preferentially in those tumors of adolescents and adults that are frequently located laterally in the cerebellar hemispheres. In DMBs, p75NTR was expressed predominantly in the proliferative, reticulin-rich areas, which may show coexpression of GFAP. In the pale islands of DMB, p75NTR was expressed only weakly or was absent. The expression pattern showed an inverse relation to that of the synaptic vesicle protein synaptophysin that was predominant in p75NTR negative classic MBs. Since the neurotrophin receptor p75NTR is expressed in cells of the external granule cell layer (EGL) of the fetal cerebellum, our findings suggest that progenitor cells of the EGL are the cellular origin of a distinct subset of MB, namely the desmoplastic variant and MBs with a significant desmoplastic component.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744061     DOI: 10.1093/jnen/59.3.229

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  32 in total

Review 1.  Medulloblastoma: therapy and biologic considerations.

Authors:  Timothy R Gershon; Orren J Becher
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 2.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

3.  Physiological purkinje cell death is spatiotemporally organized in the developing mouse cerebellum.

Authors:  Jakob Jankowski; Andreas Miething; Karl Schilling; Stephan L Baader
Journal:  Cerebellum       Date:  2009-02-24       Impact factor: 3.847

4.  Pleiotropic role for MYCN in medulloblastoma.

Authors:  Fredrik J Swartling; Matthew R Grimmer; Christopher S Hackett; Paul A Northcott; Qi-Wen Fan; David D Goldenberg; Jasmine Lau; Selma Masic; Kim Nguyen; Slava Yakovenko; Xiao-Ning Zhe; Heather C Flynn Gilmer; Rodney Collins; Mai Nagaoka; Joanna J Phillips; Robert B Jenkins; Tarik Tihan; Scott R Vandenberg; C David James; Kohichi Tanaka; Michael D Taylor; William A Weiss; Louis Chesler
Journal:  Genes Dev       Date:  2010-05-15       Impact factor: 11.361

5.  Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.

Authors:  Tobias Rausch; David T W Jones; Marc Zapatka; Adrian M Stütz; Thomas Zichner; Joachim Weischenfeldt; Natalie Jäger; Marc Remke; David Shih; Paul A Northcott; Elke Pfaff; Jelena Tica; Qi Wang; Luca Massimi; Hendrik Witt; Sebastian Bender; Sabrina Pleier; Huriye Cin; Cynthia Hawkins; Christian Beck; Andreas von Deimling; Volkmar Hans; Benedikt Brors; Roland Eils; Wolfram Scheurlen; Jonathon Blake; Vladimir Benes; Andreas E Kulozik; Olaf Witt; Dianna Martin; Cindy Zhang; Rinnat Porat; Diana M Merino; Jonathan Wasserman; Nada Jabado; Adam Fontebasso; Lars Bullinger; Frank G Rücker; Konstanze Döhner; Hartmut Döhner; Jan Koster; Jan J Molenaar; Rogier Versteeg; Marcel Kool; Uri Tabori; David Malkin; Andrey Korshunov; Michael D Taylor; Peter Lichter; Stefan M Pfister; Jan O Korbel
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

6.  Differential expression of SOX4 and SOX11 in medulloblastoma.

Authors:  Ching-Jung Lee; Vanessa J Appleby; Alex T Orme; Wai-In Chan; Paul J Scotting
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

7.  Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.

Authors:  Tea Blom; Annariikka Roselli; Valtteri Häyry; Olli Tynninen; Kirmo Wartiovaara; Miikka Korja; Kristiina Nordfors; Hannu Haapasalo; Nina N Nupponen
Journal:  J Neurooncol       Date:  2009-09-25       Impact factor: 4.130

8.  Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.

Authors:  Duane A Mitchell; Weihua Xie; Robert Schmittling; Chris Learn; Allan Friedman; Roger E McLendon; John H Sampson
Journal:  Neuro Oncol       Date:  2007-10-19       Impact factor: 12.300

Review 9.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

10.  MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.

Authors:  Livia Garzia; Immacolata Andolfo; Emilio Cusanelli; Natascia Marino; Giuseppe Petrosino; Daniela De Martino; Veronica Esposito; Aldo Galeone; Luigi Navas; Silvia Esposito; Sara Gargiulo; Sarah Fattet; Vittoria Donofrio; Giuseppe Cinalli; Arturo Brunetti; Luigi Del Vecchio; Paul A Northcott; Olivier Delattre; Michael D Taylor; Achille Iolascon; Massimo Zollo
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.